【Abstract】 Objective To explore the effects of liraglutide on blood visfatin, leptin (Lp) and insulin resistance in patients with type 2 diabetes mellitus (T2DM). Methods 98 patients with T2DM admitted between January 2016 and July 2018 were collected and divided into liraglutide group (n = 52) and dipeptidyl peptidase-4 (DPP-4 group, n= 46) according to the treatment methods. Liraglutide group was given subcutaneous injection of liraglutide for 0. 6 〜1. 2 mg/ time. DPP-4 group was given oral sitagliptin for 100 mg/time, and the two groups were continuously treated for 24 weeks. The blood glucose [fasting plasma glucose (FPG) , postprandial 2h blood glucose (2hPG) , glycosylated hemoglobin (HbAlc)], blood lipids indexes [total cholesterol (TO, triglyceride (TG) , low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)], visfatin, Lp and insulin resistance index ( HOMA-IR) were compared before and after treatment. The body weight, waist-to-hip ratio and body mass index (BMI) were recorded in the two groups before and after treatment. The occurrence of adverse reactions was observed. Results Before treatment, there were no significant differences in the blood glucose, blood lipida, visfatin, Lp, fasting insulin (FINS) , HOMA-IR, body weight, waist-to-hip ratio and BMI between the two groups (P>0. 05). At 24 weeks of treatment, the FPG, 2hPG, HbAlc, TC, visfatin, Lp, FINS, HOMA-IR, body weight, waist-to-hip ratio and BMI in liraglutide group were lower than those in DPP-4 group (P＜0. 05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0. 05). Conclusion Liraglutide has good hypoglycemic effects on T2DM, can improve insulin resistance, down-regulate TC, visfatin and Lp, and reduce body weight, waist-to-hip ratio and BMI.